-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Cube Info
Author: info
On April 1, the CDE official website showed that Pfizer's 20-valent pneumococcal polysaccharide conjugate vaccine (PREVNAR 20, PCV20) has been accepted by the State Food and Drug Administration for clinical applications in China
The product was approved by the U.
PREVNAR 20 is an upgraded version of Pfizer's ace product PCV13 (Prevnar 13).
According to the financial report, PCV13 and PCV20 will bring Pfizer $5.
It is reported that domestic companies Wantai Bio/Jiangsu Kunli are also developing a 20-valent pneumococcal polysaccharide conjugate vaccine
On January 29, 2021, Wantai Bio and Jiangsu Kunli signed the "Pneumonia 20-valent Pneumonia Candidate Vaccine Licensing Agreement", and the production, manufacture and sale of the pneumolysin-carrier 20-valent pneumococcal polysaccharide protein conjugate vaccine in mainland China Transfer of rights (exclusive license) to Wantai Bio
Note: The original text has been deleted